Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ursula A Matulonis

Showing results (81-90 of 215) with videos related to

Pageof 22
Sort By:
Gynecologic Oncology|November 24, 2020
Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancerHuma Q Rana, Lindsay Kipnis, Kristin Hehir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2016
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion StudyKathleen N Moore, Lainie P Martin, David M O'Malley, et al.
Gynecologic Oncology Reports|July 18, 2025
Phase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcomaStephanie Cham, Niya Xiong, Nabihah Tayob, et al.
Gynecologic Oncology|December 28, 2018
A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group studyUrsula A Matulonis, Michael W Sill, Vicky Makker, et al.
British Journal of Cancer|June 27, 2022
Pre-diagnosis and post-diagnosis dietary patterns and survival in women with ovarian cancerNaoko Sasamoto, Tianyi Wang, Mary K Townsend, et al.
Gynecologic Oncology|November 20, 2009
Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumorsMaria R Roche, Pandora J Rudd, Carolyn N Krasner, et al.
Gynecologic Oncology|July 19, 2005
A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trialAnna Berkenblit, Ursula A Matulonis, Joan F Kroener, et al.
Journal of Cancer Research and Clinical Oncology|November 21, 2019
Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOC patients treated with buparlisib and olaparibJulia Eismann, Yujing J Heng, Johannes M Waldschmidt, et al.
Gynecologic Oncology|August 28, 2017
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansineLainie P Martin, Jason A Konner, Kathleen N Moore, et al.
Gynecologic Oncology|March 19, 2021
Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trialsRoni Nitecki, Alexander Melamed, Allison A Gockley, et al.
Pageof 22

Showing results (81-90 of 215) with videos related to

Sort By:
Pageof 22
Gynecologic Oncology|November 24, 2020
Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancerHuma Q Rana, Lindsay Kipnis, Kristin Hehir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2016
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion StudyKathleen N Moore, Lainie P Martin, David M O'Malley, et al.
Gynecologic Oncology Reports|July 18, 2025
Phase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcomaStephanie Cham, Niya Xiong, Nabihah Tayob, et al.
Gynecologic Oncology|December 28, 2018
A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group studyUrsula A Matulonis, Michael W Sill, Vicky Makker, et al.
British Journal of Cancer|June 27, 2022
Pre-diagnosis and post-diagnosis dietary patterns and survival in women with ovarian cancerNaoko Sasamoto, Tianyi Wang, Mary K Townsend, et al.
Gynecologic Oncology|November 20, 2009
Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumorsMaria R Roche, Pandora J Rudd, Carolyn N Krasner, et al.
Gynecologic Oncology|July 19, 2005
A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trialAnna Berkenblit, Ursula A Matulonis, Joan F Kroener, et al.
Journal of Cancer Research and Clinical Oncology|November 21, 2019
Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOC patients treated with buparlisib and olaparibJulia Eismann, Yujing J Heng, Johannes M Waldschmidt, et al.
Gynecologic Oncology|August 28, 2017
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansineLainie P Martin, Jason A Konner, Kathleen N Moore, et al.
Gynecologic Oncology|March 19, 2021
Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trialsRoni Nitecki, Alexander Melamed, Allison A Gockley, et al.
Pageof 22